Cases & Deals

  • Home
  • Practices
  • ScinoPharm enters into strategic alliance with Baxter for generic oncology injectables

Share

ScinoPharm enters into strategic alliance with Baxter for generic oncology injectables

February 2017

Client(s) ScinoPharm Taiwan, Ltd.

Jones Day advised ScinoPharm Taiwan, Ltd., a leading process R&D and API manufacturer with research and manufacturing facilities in both Taiwan and China, in a strategic alliance with Baxter International to develop, manufacture, and commercialize five injectable cancer drugs, with a current market of $4 billion, with an option to add an additional 15 injectable molecules. Baxter and ScinoPharm will collaborate on product development and manufacturing with Baxter having the right to commercialize the drugs.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.